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Abstract
Background: Neonatal death in full-term infants who suffer from perinatal asphyxia (PA) is a major subject of investigation,
since few tools exist to predict patients at risk of ominous outcome. We studied the possibility that urine S100B
measurement may identify which PA-affected infants are at risk of early postnatal death.
Methodology/Principal Findings: In a cross-sectional study between January 1, 2001 and December 1, 2006 we measured
S100B protein in urine collected from term infants (n=132), 60 of whom suffered PA. According to their outcome at 7 days,
infants with PA were subsequently classified either as asphyxiated infants complicated by hypoxic ischemic encephalopathy
with no ominous outcome (HIE Group; n=48), or as newborns who died within the first post-natal week (Ominous Outcome
Group; n=12). Routine laboratory variables, cerebral ultrasound, neurological patterns and urine concentrations of S100B
protein were determined at first urination and after 24, 48 and 96 hours. The severity of illness in the first 24 hours after birth
was measured using the Score for Neonatal Acute Physiology-Perinatal Extension (SNAP-PE). Urine S100B levels were higher
from the first urination in the ominous outcome group than in healthy or HIE Groups (p,0.001 for all), and progressively
increased. Multiple logistic regression analysis showed a significant correlation between S100B concentrations and the
occurrence of neonatal death. At a cut-off .1.0 mg/L S100B had a sensitivity/specificity of 100% for predicting neonatal death.
Conclusions/Significance: Increased S100B protein urine levels in term newborns suffering PA seem to suggest a higher risk
of neonatal death for these infants.
Citation: Gazzolo D, Frigiola A, Bashir M, Iskander I, Mufeed H, et al. (2009) Diagnostic Accuracy of S100B Urinary Testing at Birth in Full-Term Asphyxiated
Newborns to Predict Neonatal Death. PLoS ONE 4(2): e4298. doi:10.1371/journal.pone.0004298
Editor: Jacqueline Ho, JARING, Malaysia
Received December 16, 2007; Accepted September 27, 2008; Published February 2, 2009
Copyright:  2009 Gazzolo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by grants (COFIN 2005) provided by the Italian Ministry of University and Scientific Research, and from the ‘‘Let’s
improve prenatal life’’ and ‘‘Stella Cometa’’ Foundations. The funding sources had no role in the design or conduct of the study, in the collection, management,
analysis, or interpretation of the data, or in the preparation, review and approval of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dgazzolo@hotmail.com
Introduction
Neonatal death in full-term infants suffering perinatal asphyxia
(PA) is a major subject of concern, since to date no clinical,
biochemical or biophysical tools exist to predict which patients are
at risk of ominous outcome [1]. Epidemiological studies have
highlighted the relevance of the timing of the hypoxic insult, which
in the majority of cases occurs in the pre-perinatal period [2]. To
date, the possibility of detecting infants at risk of this severe
complication is limited since clinical, laboratory and standard
monitoring procedures may be silent or unreliable. A practical and
sensitive marker able to offer neonatologists a useful tool for
clinical and ethical purposes is therefore eagerly awaited.
In the last decade a brain constituent, S100B protein, has been
proposed as a consolidated marker of brain damage [3], since
elevated S100B concentrations in biological fluids have been found
in brain-damaged adults, infants and fetuses [3–12]. S100B
belongs to a multigenic family of calcium-modulated proteins
(S100 proteins), mostly of low molecular weight (approximately
10,000 Da), first identified as a protein fraction detectable in brain
(in glial and Schwann cells, in specific neuronal subpopulations)
and named S100 because of its solubility in a 100% saturated
solution of ammonium sulfate [4].
With regard to perinatal medicine, it is noteworthy that S100B
has recently been shown to be a reliable diagnostic test for
predicting newborns at risk of pre-perinatal death [13,14]. Of the
biological fluids in which this protein has been assessed, urine
appears to be the most suitable, because it can be collected easily
and sampling can be repeated without additional risks for the
newborn.
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4298The present study aimed to evaluate whether the measurement
of S100B in urine may represent a useful tool to identify a risk of
early postnatal death in full-term newborns affected by PA.
Results
Clinical and laboratory parameters
At birth, no significant differences regarding weight, gestational
age and gender distribution were found between neonatal death
and control groups (P.0.05 for all). Of the 12 infants with
ominous outcome, 10 developed severe HIE whilst, in the group
complicated by PA with no ominous outcome (HIE group), 36 out
of 48 developed mild HIE and 12 out of 48 severe HIE. The
incidence of ARDS was significantly different in the neonatal
death group compared with controls (P,0.001). Clinical findings,
neonatal outcomes and laboratory parameters of all the studied
infants are shown in Tables 1 and 2. As expected, Apgar scores at
birth, at the 1
st and 5
th minutes, pH, PvCO2, and base excess were
significantly different in newborns who suffered PA (both HIE and
ominous outcome groups) and in the healthy group (P,0.001 for
all). However, no differences were found when the ominous
outcome group was compared with the HIE group (P.0.05, for
all) (Table 2), even at the 24, 48, and 96-hour time-points (P.0.05
for all) (data not shown).
The mean (SD) SNAP-PE score recorded within the first
24 hours after birth was significantly lower in healthy controls
(31.864.1) than in newborns with PA with no ominous outcome
(HIE Group: 36.268.7), and in infants who died within the first
week after birth (Ominous Outcome Group: 39.768.8) (P,0.05
for all), while not differing between the two groups with PA
classified according to their outcome (data not shown).
Neurodevelopmental outcome and cerebral ultrasound
findings
Cerebral ultrasound scans performed 24 hours from birth were
negative in the 72 uncomplicated control infants and in 20 out of
48 control infants with perinatal asphyxia. Echographic patterns
suggestive of brain edema and/or periventricular hyperechogeni-
city were observed in 28 out of 48 control infants with perinatal
asphyxia and in 10 out of 12 infants of the neonatal Ominous
Outcome Group. None of the monitored infants showed
congenital cerebral malformations or bleeding. Identical cerebral
echographic patterns were observed at the 48 and 96-hr time-
points, except for the remaining 2 infants of the neonatal death
group, in which brain edema and/or periventricular hyperecho-
genicity were apparent.
Neurological examination at NICU admission was negative in
the 72 control infants, whilst in 18 out of 48 controls with perinatal
Table 1. Maternal and neonatal characteristics at birth in infants without overt neurological syndrome [healthy group (n=72)], in
infants with asphyxia complicated by hypoxic ischemic encephalopathy with no ominous outcome (HIE Group; n=48)] and in







Mean maternal age (years) 30 31 30
Cesarean Section (yes/total) 20/20* 18/18* 31/96
Gestational age (wks) 38.462.1 38.161.6 39.161.4
Sex: Male/Female (nu) 38/34 25/23 7/5
Birth weight (g) 3,1006507 3,1986414 3,4516231
Apgar 1
st min ,7 (yes/total) 0/72 48/48 12/12
Apgar 5
th min ,7 (yes/total) 0/72 48/48 12/12
RDS (yes/total) 0/72 7/48* 0/96
Mechanical Ventilation or NCPAP support (yes/total) 0/72 33/48* 12/12
HIE according to Sarnat’s test (yes/total)
N Moderate (yes/total) 0/72 36/48* 2/12
N Severe (yes/total) 0/72 12/48* 10/12
Cerebral US (normal/hyperechogenicity/bleeding)
N Birth Not performed 28/20/0 2/10/0
N 12 hours Not performed 28/20/0 2/10/0
N 24 hours Not performed 28/20/0 0/12/0
N 72 hours 72/0/0 28/20/0 0/12/0
Prechtl’s Test (normal/suspect/abnormal)
N Birth 0/0/0* 0/18/0* 0/4/4
N 24 hours 0/0/0* 0/6/3* 0/8/4
N 48 hours 0/0/0* 0/6/3* 0/6/6
N 96 hours 0/0/0* 0/6/3* 0/6/6
SNAP-PE score at NICU admission 32643 6 694 0 69
Values are expressed as mean6SD.
*P,0.05 vs controls.
doi:10.1371/journal.pone.0004298.t001
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ity: n=7). Neurological patterns remained superimposable at the
24, 48 and 96-hr time-points. In the neonatal death group isolated
hyperexcitability (n=4) and hypo/hypertonia (n=4) symptoms
were recorded, and between the 24 and 96-hr time-points there
was an impairment in neurological examination patterns, with
hyperexcitability (n=6) and hypo/hypertonia (n=6).
In the neonatal death group 5 died within the first 120 hours
from birth and the remaining 7 newborns died of cardiopulmo-
nary failure within the first week.
Urine S100B levels and the prediction of ominous
outcome
Urine S100B protein levels were detectable in all the patients
examined. While the levels did not change during monitoring in
either healthy neonates or newborns affected by PA with a good
outcome, in the group with ominous outcome they increased,
peaking after 48 and 96 hrs (P=0.027) (Figure 1). In these infants,
S100B concentrations were significantly higher at all monitoring
time-points (P,0.001 for all) than in both healthy and HIE infants
(P,0.001 for all), whilst they did not differ between the latter two
groups (Figure 1) (Table 3).
Multiple logistic regression analysis with neonatal death as
dependent variable showed a positive significant correlation only
between S100B blood levels (P,0.001) and the occurrence of
neonatal death among a series of monitoring parameters (odds
ratio at birth and at 48 hours from birth: 11.42 and 9.15,
respectively).
On the basis of these results and the outcome after 7 days,
newborns were grouped as normal (n=120, comprising healthy
newborns and HIE infants) and pathological (n=12, infants with
PA and ominous outcome). Table 4 shows the reliability/efficiency
of S100B protein levels at different monitoring time-points in
predicting the occurrence of neurological abnormalities in IUGR
infants. As can be seen, the reliability of S100B values as a
diagnostic test was greatest from the first urination and with a cut-
off .1.0 mg/L, the value at which S100B achieved a sensitivity of
100% (CI5–95%: 73.4–100) and a specificity of 100% (CI5–95%:
96.9–100) as a single marker for predicting the occurrence of
neonatal death (area under the ROC curve: 1.000; CI5–95%:
0.972–1.0) (Table 4 and Figure 1). The predictive values of S100B
levels at the remaining time-points, at cut-offs .1.0 mg/L, gave
similar results (Table 4).
In contrast, SNAP-PE scores at the cut-off of 38 combined a
sensitivity of 50% (CI5–95%: 21.2%–78.8%) with a specificity of
88.2% (CI5–95%: 81.0%–93.4%) for predicting brain damage (area
under the ROC curve: 0.703; CI5–95%: 0.617–0.780) (Figure 1).
The SNAP-PE AUC was significantly (P=0.001) lower than that
calculated for S100B at first urination (SD: 0.0874; difference
between areas: 0.297; CI5–95%: 0.125–0.468) (data not shown).
Twelve of 132 patients died with 7 days of birth,giving an
overall neonatal death rate in our population of 9.1% (CI5–95%:
4.17%–14.02%). This was the predicted probability of ominous
outcome prior to measuring S100B (pre-test probability). With regard
to predicting neonatal death, when only S100B was available the
positive predictive value was 100.0% (CI5–95%: 98%–100%) and
the negative predictive value 100.0% (CI5–95%: 98%–100%).
When only SNAP-PE computation was available, its positive and
negative predictive values were 30.0% (CI5–95%: 9.9%–20.1%) and
5.71% (CI5–95%: 1.4%–10.0%), respectively.
Discussion
The present study provides evidence that early after a severe
hypoxic insult there is an increase in urine concentrations of
S100B, a brain constituent, and that such an increase only occurs
in asphyxiated infants who will have a poor neonatal outcome, i.e.
neonatal death within 7 postnatal days. The results in healthy
controls and in infants suffering hypoxic ischemic encephalopathy
but not ominous outcome fit with previous observations [15,16].
The data relating to asphyxiated newborns with ominous
outcome are consistent with previous observations, in which the
presence of elevated S100B protein concentrations in biological
fluids (amniotic fluid, urine and blood) correlated with: i) the
occurrence of unexplained fetal death in the third trimester of
pregnancy [13]; ii) the occurrence of an ominous outcome in the
first week of age, in preterm infants [14]; iii) the possibility to
evaluate cerebral death in adult patients when S100B measure-
ment is included among peri-mortem procedures [17].
The fact that S100B is known to be essentially absent from the
kidney [18], and the evidence that early and severe damage to the
central nervous system is reasonably held to be responsible for a
continuous release of S100B protein into the systemic circulation
and, finally, into the urine [3,14], together support the concept
that: i) the notably high concentrations of the protein detected in
urine originate in the nervous system; ii) the release of S100B
constitutes a warning sign of severe brain insults, and; iii) a higher
secretion of S100B correlates with more severe brain injury.
Indeed, the same pattern of increased S100B in urine has been
shown in infants suffering perinatal complications such as acute
and chronic hypoxia [15,16,19], cerebral bleeding [3,10,11], or
during risky procedures for life-threatening conditions (extracor-
poreal membrane oxygenation, cardiopulmonary by-pass) [20,21].
S100B may be released, at least in part, from other sites in
which it is concentrated, such as adipose tissue and placenta
Table 2. Neonatal monitoring parameters at birth in infants
without overt neurological syndrome [healthy (n=72) and HIE
(n=48) Groups] and in newborns affected by PA and with












3) 4.160.5 3.9160.5 3.9360.3
Hemoglobin (g/dL) 13.860.2 13.760.2 13.660.4
Hematocrit rate % 41.561.5 41.262.2 40.761.9
Venous blood pH 7.3460.1 7.0560.1* 7.0060.1*
Partial venous CO2 pressure (mmHg) 42.464.1 78.669.2* 61.6617.5*
Partial venous O2 pressure (mmHg) 41.264.9 17.167.6 31.6623.4
Base excess 0.462.1 212.362.2* 214.165.1*
Na
+ (mmol/L) 141631 3 8 651 4 0 63
K
+ (mmol/L) 4.160.3 4.760.3 4.160.2
Ca
++ (mmol/L) 1.1960.02 1.1160.06 1.1260.1
Plasma glucose (mmol/L) 4.260.2 4.261.1 4.161.2
Urea (mg/dL) 39.268.8 35.2615.8 42.6610.6
Creatinine (mg/dL) 0.8160.3 0.8760.28 0.9360.11
Urine gravity 1,01064.4 1,01262.4 1,01163.3
Values are expressed as mean6SD.
*P,0.05 vs healthy Group.
Abbreviations: RBC: Red Blood Cells
doi:10.1371/journal.pone.0004298.t002
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adipocytes are currently inconclusive, while a placental origin can
be reasonably excluded, bearing in mind the limited half-life of the
protein (about 1hour) [24].
In the present study we also demonstrated the possibility of
identifying newborns at higher risk of early neonatal death in the
first hours after birth. Indeed, measuring S100B in the urine of
asphyxiated newborns at a stage when standard diagnostic
procedures are still silent or unreliable yields positive and negative
predictive values relating to the early detection of infants at risk of
ominous outcome. S100B was the only parameter that correlated
with the occurrence of neonatal death (as shown by multiple
logistic regression analysis). Moreover, we found that in newborns
with urine S100B levels above the thresholds defined by the ROC
curve analysis (.1.0 mL) the probability (positive predictive value)
of neurological sequelae was as high as 100%, while it was 0% if
these levels were below the threshold: these concentrations thus
showed positive and negative predictive values that differ from the
Figure 1. S100B levels in urine at first urination. S100B concentrations were significantly (p,0.001) higher in newborns who died within the
first week of age (Ominous Outcome Group: black triangles) than in healthy controls (open circles), and in infants suffering PA without ominous
outcome (HIE Group: open squares). ROC curve analysis shows that the S100B measurement as a diagnostic test has a sensitivity and a specificity of
100% at a cut-off of 1.0 mg/L (shown by the dotted line) with 100% positive predictive value and 100% negative predictive value. Horizontal bars
indicate the median value for each group. *P,0.05 versus 24 h and ,0.01 versus 96 h monitoring time-points.
doi:10.1371/journal.pone.0004298.g001
Table 3. Urine S100B concentrations (mg/L) expressed as median [lower and upper 95% Confidence Interval (CI)] at first urination
(0), and at 24 (1), 48 (2) and 96 (3) hours in healthy Group (n=72), in newborns affected by PA without overt neurologic syndrome
(n=48, HIE Group) and with ominous outcome (n=12, Ominous Outcome Group).
S100B (mg/L) Healthy Group (n=72) HIE Group (n=48) Ominous Outcome Group (n=12)
Median Lower CI95% Upper CI95% Median Lower CI95% Upper CI95% Median Lower CI95% Upper CI95%
First urination (0)* 0.1 0.15 0.23 0.23 0.17 0.31 3.0 2.94 3.63
24 hours (1)* 0.05 0.12 0.19 0.12 0.12 0.2 4.25 3.52 6.27
48 hours (2)* 0.12 0.15 0.23 0.21 0.17 0.29 6.0 4.4 9.26
96 hours (3)* 0.2 0.16 0.24 0.25 0.2 0.31 4.45 4.22 11.64
Urinary S100B levels were significantly higher in the neonatal death group at all monitoring time-points (p,0.001, for all).
*p,0.001 vs controls
doi:10.1371/journal.pone.0004298.t003
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population. These findings would need to be confirmed in larger
similar studies, since the sample size of the present study was fairly
small. They nonetheless appear relevant, since neurological
examination and other standard monitoring procedures were
unable to detect which asphyxiated infants would develop an
adverse neurological outcome and which would not. S100B
appears to satisfy the criteria required for a marker in perinatal
medicine: i) good reproducibility and simple performance of
measurements: the immunoluminometric assay for protein
quantification is rapid (about 1-h), inexpensive and simple to
perform; ii) detection in a wide range of biological fluids, offering
the possibility of reducing perinatal stress; iii) possible employment
in longitudinal monitoring, thanks to to its half-life; iv) well-
established use as an early and quantitative marker of brain lesion.
Urine samples are, moreover, much more easily collected than
blood, which is usually required for other brain marker
procedures, and are thus more convenient, bearing in mind that
the need for repeated blood sampling is widely known to be
associated with a risk of anemia [25]. The use of urine samples
thus benefits the care of high-risk newborns. Factors such as
oliguria and renal failure or the effects of sedative drugs that might
complicate or hinder the collection of urine samples, especially in
the first hours after birth, were not encountered in the present
study, partly because of the small amount of urine needed for
S100B protein measurements (100 mL).
In conclusion, in the present study we found that asphyxiated
newborns who later died had high S100B levels in urine, and that
the measurement of this protein offers additional support in
clinical practice, as a further parameter able to identify newborns
at risk. Indeed, the early increase in S100B urine concentrations,
due to an early release of the protein from the brain, may offer a
direct indicator of active cell damage at a stage when standard
diagnostic procedures are unable to detect patients at risk, and
may represent a warning sign of impending neonatal death.
Materials and Methods
Participants
Between January 1, 2001 and December 1, 2006 we performed
a cross-sectional study with urine collected consecutively at our
tertiary referral centers for Neonatal Intensive Care Units (NICUs)
from 132 term newborns (37–42 wks of gestation; mean
3962 wks), of whom 72 (mean6SD gestational age: 3961 wks)
were healthy with no overt neurological syndrome (healthy group)
and the remaining 60 suffered perinatal asphyxia (PA).
The healthy group was composed of newborns who developed
jaundice and were hospitalized for 96 hrs in order to investigate
blood bilirubin levels and blood pH (including ion concentrations)
in the postnatal period (i.e. 24, 48 and 96 hrs ). Newborns who
suffered PA were subsequently classified, according to their
outcome at 7 days, either as asphyxiated infants complicated by
hypoxic ischemic encephalopathy (HIE) with no ominous outcome
(HIE Group, n=48), and infants who died within the first week
after birth (Ominous Outcome Group; n=12; mean6SD
gestational age: 3962 wks). Informed written consent was
obtained from all parents of patients prior to inclusion in the
study, for which local (Gaslini Children’s Hospital University of
Genoa and Department of Neonatology, Cairo University)
Human Investigations Committee approval was obtained.
All asphyxiated newborns were delivered by emergency
cesarean section due to acute fetal distress, defined according to
the American College of Obstetricians and Gynecologists as non-
reassuring fetal status (bradycardia, late deceleration of the fetal
heart rate, severe and repetitive variable deceleration of the fetal
heart rate, reduced beat-to-beat variability). Asphyxia was defined
according to an Apgar score of ,3 at the 5
th minute, pH ,7.0, or
BE,212 in cord blood or venous blood taken from newborns
within 60 min after birth, or the need for positive pressure
ventilation (.3 minutes) [26]. Infants who met 3 or more of the
above clinical and biochemical parameters were included in the
asphyxia group. All patients had a normal karyotype and were free
of detectable anomalies; fetuses with malformations or congenital
heart disease and those born to women exposed to alcohol or
tobacco smoke were excluded from the study. Other exclusion
criteria were congenital or perinatal infections including chorio-
amnionitis, intrauterine growth retardation, multiple pregnancies,
maternal drug addiction.
On admission to the NICU we routinely assessed the clinical
parameters of all newborns [red blood cell count (RBC), venous
blood pH, ion concentrations, plasma glucose levels], and
performed a daily neurological examination [27].
S100B protein levels were measured in urine at first urination
(time 0) and 24 (time 1), 48 (time 2) and 96 (time 3) hrs after birth.
The first urination occurred within the first 6 hours after birth
(mean 3 hours). In this regard, the healthy group included only
Table 4. Sensitivity, specificity and predictive values at different monitoring time-points of serial urinary S100B levels as diagnostic
test for early neonatal death detection, at cut-off (.1 mL) identified by the ROC curve analysis.
Monitoring PPV (%) NPV (%) Sens (%) Spec (%) AUC
Time-points (CI5–95%)( C I 5–95%)( C I 5–95%)( C I 5–95%)( C I 5–95%)
First urination 100.0 100.0 100 100 1.0
(98–100) (98–100) (73.4–100.0) (96.9–100.0) (0.972–1.000)
24 hours 100.0 100.0 100 100 1.0
(98–100) (98–100) (73.4–100.0) (96.9–100.0) (0.972–1.000)
48 hours 100.0 100.0 100 100 1.0
(98–100) (98–100) (73.4–100.0) (96.9–100.0) (0.972–1.000)
96 hours 100.0 100.0 100 100 1.0
(98–100) (98–100) (73.4–100.0) (96.9–100.0) (0.972–1.000)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; Sens, sensitivity; Spec, specificity; AUC, area under the curve; CI5–95%, lower and upper
95% Confidence Interval.
doi:10.1371/journal.pone.0004298.t004
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during the collection times.
The results were correlated with the occurrence or not of
ominous outcome within 7 days after birth. Cerebral ultrasound
and neurological patterns were assessed at the same time as urine
sampling by a single examiner in each Center who did not know
the results of the urine test. Finally, the severity of illness in the first
24 hrs after birth was measured using the Score for Neonatal
Acute Physiology-Perinatal Extension (SNAP-PE) [28].
Cranial Assessment
Standard cerebral ultrasonography was performed by a real-
time ultrasound machine (Acuson 128SP5, Mountain View CA,
USA) using a transducer frequency emission of 3.5 MHz.
Neurodevelopmental outcome
In the asphyxiated group, the presence within the first 7 days
after birth of HIE was classified according to the criteria described
by Sarnat and Sarnat [29]. HIE was defined as mild if
hyperexcitability or hypotonia persisted without seizures for at
least 72 hours after birth; as moderate if the infant was lethargic
and had hypotonia, weak primitive reflexes, and seizures; and as
severe if the infant showed frequent seizures, apnea, flaccid
weakness, or coma. EEG traces were recorded in the asphyxiated
infants within the first 5 days from birth.
Neurological examination was performed at the same time-points
as urine sampling. Neonatal neurological conditions were classified
using a qualitative approach as described by Prechtl [27], assigning
each infant to one of three diagnostic groups: normal, suspect or
abnormal. An infant was considered to be abnormal when one or
more of the following neurological syndromes was present: hyper- or
hypokinesia, hyper- or hypotonia, hemisyndrome, apathy syndrome,
hyperexcitability syndrome. An infant was classified as suspect if only
isolated symptoms were present but no defined syndrome.
S100B measurement
Urine samples were collected at each time-point, immediately
centrifuged at 900 g for 10 min, and stored at 270uC. We
measured S100B in urine using a commercially available
immunoluminometric assay (Lia-mat Sangtec 100, AB Sangtec
Medical, Bromma, Sweden), and measurements were performed
in duplicate according to the manufacturer’s instructions. This
assay is specific for the b subunit of the S100 protein and measures
the b subunit using three MAb (SMST 12, SMSK 25 and SMSK
28). The b subunit of the S100 protein is known to be
predominant (80–96%) in the human brain [30,31]. The assay
detection limit was 0.02 mg/L: precision was less than 5.5% for
intra-assay and less than 10.1% for inter-assay.
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate whether the
distributionofdatawasGaussian.Comparisonbetweenproportions
was performed using Fisher’s exact test. Comparison of fetal and
neonatal monitoring parameters between groups was performed by
the Mann-Whitney U test, Kruskal-Wallis one way ANOVA
followed by post-hoc Dunn’s test when the data were not normally
distributed. Changes in S100B levels [median, lower and upper
95% Coefficient Intervals (CI)] in urine at the different monitoring
time-points were evaluated using the repeated-measures ANOVA
test followed by post-hoc Tukey’s Multiple Comparison Test, and
Friedman’s test followed by post-hoc Dunn’s Multiple Comparison
Test when the data were not normally distributed. Differences
between groups were tested using the Mann-Whitney U test.
Multiple forward stepwise regression analysis was performed
with S100B as the dependent variable to analyze the influence of
various clinical parameters [renal function, gender, gestational
age, maternal antenatal steroid treatment, presence or absence of
antenatal infection, normal or abnormal neurological follow-up at
one week of age, delivery mode, Apgar scores at 1 and 5 minutes,
birthweight, incidence of Respiratory Distress Syndrome (RDS)]
on the occurrence of neonatal death.
We used the cut-off indicated by Receiver Operating Charac-
teristic (ROC) analysis [32,33] to evaluate the positive and negative
predictive values, specificity and sensitivity, and likelihood ratios
with their respective 95% confidence bounds. Thus, we estimated
the probability of neonatal death in asphyxiated newborns and
compared it with the pretest probability, defined as the prevalence
of neonatal death in the whole group of patients [34].
Statistical analysis was performed using the GraphPad Prism
version 3.00 for Windows (GraphPad Software, Inc., San Diego,
CA). A value of P,0.05 was considered significant.
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